INIFY Laboratories AB (OSL:INIFY) ROCE % : -139.24% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is INIFY Laboratories AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. INIFY Laboratories AB's annualized ROCE % for the quarter that ended in Dec. 2024 was -139.24%.

INIFY Laboratories AB ROCE % Historical Data

The historical data trend for INIFY Laboratories AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

INIFY Laboratories AB ROCE % Chart

INIFY Laboratories AB Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

ROCE %

-50.04

-86.54

INIFY Laboratories AB Quarterly Data
	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial						-64.74	-59.67	-81.50	-89.64	-139.24

INIFY Laboratories AB ROCE % Calculation

INIFY Laboratories AB's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-52.607	/	( ( (95.646 - 8.18)	+	(43.821 - 9.703) )	/ 2 )
	=	-52.607	/	( (87.466	+	34.118)	/ 2 )
	=	-52.607	/	60.792
	=	-86.54 %

INIFY Laboratories AB's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-58.204	/	( ( (57.621 - 8.136)	+	(43.821 - 9.703) )	/ 2 )
	=	-58.204	/	( ( 49.485	+	34.118 )	/ 2 )
	=	-58.204	/	41.8015
	=	-139.24 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

INIFY Laboratories AB (OSL:INIFY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

INIFY Laboratories AB ROCE % Related Terms

Thank you for viewing the detailed overview of INIFY Laboratories AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

INIFY Laboratories AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » INIFY Laboratories AB (OSL:INIFY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Scheeles vag 3, Solna, SWE, 171 65

Website

https://www.inify.com

INIFY Laboratories AB provides cancer diagnostics through ultra-modern laboratory services within pathology. It uses a fully digital, standardized, and AI-supported workflow to optimize quality and response times, initially within the prostate. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer's organization.

INIFY Laboratories AB Headlines

No Headlines